Furthermore, we found that HELLS is co-expressed with PARP1 in cancer cells, and its loss is synthetic lethal with homologous recombination deficiency (HRD). The gene discussed is HELLS; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.